Loading institutional data...
Loading institutional data...
Institutional ownership roughly stable: +0.00% change quarter-over-quarter.
Data as of Q1 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading quality & risk...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Solve the discounted cash flow backwards, then stress-test the assumptions.
To be worth $7.35 today, the market must believe free cash flow compounds 3.9%/yr for a decade (off $111M normalized FCF).
The market's 3.9% is more conservative than its 5-yr track record.
2-stage DCF · 0.23B shares · net debt -$27M
mean 687.5% · volatility σ 1348% · implied rate exceeded in 2/3 yrs
Central path = implied 3.9%/yr growth; shaded band = ±1σ (1348%) of this company's historical FCF volatility, widening with time. The wider the band, the less certain the growth.
Reverse DCF: rather than guessing a fair value, we solve for the growth the current price implies, then you stress-test the assumptions. Enterprise value of the FCF stream, less net debt, ÷ shares. Educational — not a recommendation.
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
Is the value real, and is the business safe? Academic scores + earnings quality + solvency, from SEC filings.
Insufficient balance-sheet detail (needs retained earnings, working capital, equity).
Eight indices comparing this year to last (receivables, margins, asset quality, growth, accruals, leverage). Above −1.78 suggests possible manipulation; below −2.22 is clean.
A screen, not proof — high growth alone can raise it.
Earnings are backed by cash (FCF ≥ net income) — high quality. Lower/negative accruals = higher quality (Sloan).
Comfortably covers interest; leverage rising year-over-year.
F-Score (0–9 fundamental momentum), Altman Z (distress risk), and Beneish M (earnings-manipulation screen) are academic models computed from the SEC filings. Screens and context — educational, not recommendations.
What the company returns to shareholders — and whether it's covered by cash.
No dividend to cover. Last year: $0 dividends + $0 buybacks = $0 returned on $214M FCF.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 8 years — and what it earned on reinvestment.
A reinvestment story — most cash went back into growth rather than to shareholders.
Modest payoff on reinvested capital. Current ROIC on all capital: 5%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 8 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Cash of $274M covers all $247M of scheduled principal — no refinancing pressure. Scheduled principal only (excludes interest & revolver draws). As of 2025-12-31 (10-K).
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Interest is easily covered by operating profit. Effective rate ~8.1% on $247M of debt.
Cash vs short-term debt unavailable.
Mostly long-term debt (balance-sheet current vs non-current split). See the maturity ladder above for the year-by-year repayment schedule.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Maturity ladder from the SEC long-term-debt repayment schedule. Educational — not a recommendation.
EOD close · as of 2026-09-17
No material risks flagged.
Where each multiple sits in its own 8-yr range · 0th pct blended
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 8-yr history.
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
Watch the leverage lever — a chunk of ROE comes from the balance sheet.
What the company owes vs. what it holds
Year-by-year maturities aren't in SEC companyfacts (footnote-only), so this shows the debt/cash structure and net leverage instead.
Latest year: profit growth vs revenue growth
Profit and sales moved in opposite directions this year.
Each line as % of revenue — the trend in color
| % of revenue | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | 54.7 | 50.5 | 45.3 | 44.9 | 50.5 | 50.1 | 47.1 | 51.1 |
| Gross Profit | 45.3 | 49.5 | 54.7 | 55.1 | 49.5 | 49.9 | 52.9 | 48.9 |
| SG&A | 87.5 | 62.2 | 35.6 | 31.0 | 28.9 | 32.4 | 33.1 | 37.2 |
| Operating Income | -42.1 | -12.8 | 19.1 | 24.0 | 11.9 | 17.5 | 19.7 | 11.7 |
| Income Tax | 11.5 | 4.3 | 15.1 | 13.9 | 9.3 | 11.2 | 11.1 | 12.5 |
| Net Income | -8.4 | -27.3 | 2.7 | 8.4 | 1.2 | 3.4 | 6.4 | 9.7 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on GTBIF: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.
EOD close · as of 2026-09-17
How a revenue dollar becomes profit — FY2025
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.18B 100.0% | $1.14B 100.0% | $1.05B 100.0% | $1.02B 100.0% | $893.6M 100.0% | $556.6M 100.0% | $216.4M 100.0% | $62.5M 100.0% |
| Cost of Revenue | $600.4M 51.1% | $536.0M 47.1% | $528.1M 50.1% | $513.4M 50.5% | $401.6M 44.9% | $252.4M 45.3% | $109.4M 50.5% | $34.2M 54.7% |
| Gross Profit | $574.9M 48.9% | $601.1M 52.9% | $526.5M 49.9% | $504.0M 49.5% | $491.9M 55.1% | $304.2M 54.7% | $107.0M 49.5% | $28.3M 45.3% |
| Selling, General & Admin | $437.2M 37.2% | $376.7M 33.1% | $341.9M 32.4% | $294.4M 28.9% | $277.1M 31.0% | $198.1M 35.6% | $134.7M 62.2% | $54.7M 87.5% |
| Total Operating Expenses | $437.2M 37.2% | $376.7M 33.1% | $341.9M 32.4% | $382.9M 37.6% | $277.1M 31.0% | $198.1M 35.6% | $134.7M 62.2% | $54.7M 87.5% |
| Operating Income | $137.7M 11.7% | $224.4M 19.7% | $184.6M 17.5% | $121.1M 11.9% | $214.8M 24.0% | $106.1M 19.1% | -$27.7M -12.8% | -$26.3M -42.1% |
| Interest Expense | $20.0M 1.7% | $24.3M 2.1% | $19.1M 1.8% | $21.2M 2.1% | $22.0M 2.5% | $18.7M 3.4% | $13.7M 6.3% | $2.3M 3.6% |
| Interest & Investment Income | $11.4M 1.0% | $9.1M 0.8% | $6.7M 0.6% | $4.1M 0.4% | $1.4M 0.2% | $114K 0.0% | $1.5M 0.7% | $2.0M 3.1% |
| Other Income (Expense), net | $125.7M 10.7% | -$24.3M -2.1% | -$28.6M -2.7% | -$12.6M -1.2% | -$9.9M -1.1% | -$3.2M -0.6% | -$22.5M -10.4% | $56.1M 89.8% |
| Pretax Income | $263.4M 22.4% | $200.1M 17.6% | $156.0M 14.8% | $108.4M 10.7% | $205.0M 22.9% | $102.9M 18.5% | -$50.2M -23.2% | $29.8M 47.6% |
| Income Tax Expense | $147.3M 12.5% | $126.3M 11.1% | $118.6M 11.2% | $94.8M 9.3% | $124.6M 13.9% | $83.9M 15.1% | $9.3M 4.3% | $7.2M 11.5% |
| Net Income | $114.2M 9.7% | $73.1M 6.4% | $36.3M 3.4% | $12.0M 1.2% | $75.4M 8.4% | $15.0M 2.7% | -$59.1M -27.3% | -$5.2M -8.4% |
| Per Share | ||||||||
| EPS (Basic) | $0.49 | $0.31 | $0.15 | $0.05 | $0.34 | $0.07 | $-0.31 | $-0.04 |
| EPS (Diluted) | $0.48 | $0.30 | $0.15 | $0.05 | $0.33 | $0.07 | $-0.31 | $-0.04 |
| Weighted Avg Shares (Basic) | 233.9M | 236.8M | 237.9M | 236.7M | 223.2M | 211.0M | 190.6M | 130.1M |
| Weighted Avg Shares (Diluted) | 236.9M | 241.9M | 239.8M | 238.1M | 226.8M | 212.5M | 190.6M | 130.1M |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
Ranked against 1085 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-03-31.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BCAX | $1.24T | — | — | — | — | — | — | -34.4% | -34.4% | — | 143 |
| LLY | $1.03T | 50.2× | — | 15.9× | 44.7% | 83.0% | 31.7% | 77.8% | 29.9% | — | 4,193 |
| AKTX | $894.1B | — | — | — | — | — | — | -61.1% | -61.1% | — | 1 |
| JNJ | $650.5B | 24.5× | — | 6.9× | 6.0% | 67.9% | 28.5% | 32.9% | 20.7% | — | 4,451 |
| ABBV | $467.1B | 111.9× | 33.4× | 7.6× | 8.6% | 70.2% | 6.9% | -129% | 6.6% | 4.2× | 3,895 |
| MRK | $368.2B | 20.2× | — | 5.7× | 1.3% | 74.8% | 28.1% | 34.7% | 17.9% | — | 3,594 |
| UNH | $339.9B | 28.4× | 19.7× | 0.8× | 11.8% | 88.7% | 2.7% | 12.0% | 6.8% | 3.9× | 2,891 |
| AZN | $257.7B | — | — | — | — | — | — | — | — | — | 1,248 |
| TMO | $248.2B | 37.1× | 31.9× | 5.6× | 3.9% | — | 15.0% | 12.6% | 7.0% | 4.9× | 2,481 |
| AMGN | $204.6B | 26.7× | 17.6× | 5.6× | 10.0% | 67.2% | 21.0% | 89.1% | 12.2% | 3.8× | 3,014 |
| GILD | $187.3B | 22.3× | 20.4× | 6.4× | 2.4% | 78.8% | 28.9% | 37.5% | 17.9% | 2.4× | 2,218 |
| ABT | $178.0B | 27.5× | 19.2× | 4.0× | 5.7% | 56.4% | 14.7% | 12.5% | 10.0% | 1.4× | 2,964 |
| PFE | $157.1B | 20.3× | — | 2.5× | -1.6% | 74.3% | 12.4% | 9.0% | 5.1% | — | 2,838 |
| DHR | $150.2B | 42.1× | 31.0× | 6.1× | 2.9% | 59.1% | 14.7% | 6.9% | 5.1% | 3.4× | 2,083 |
| ISRG | $136.2B | 48.7× | 37.5× | 13.5× | 20.5% | 66.0% | 28.4% | 16.0% | 16.0% | — | 2,190 |
| VRTX | $131.1B | 33.7× | 28.8× | 10.9× | 8.9% | 86.2% | 32.9% | 21.2% | 21.2% | — | 1,609 |
| BMY | $127.8B | 18.2× | — | 2.6× | -0.2% | 71.1% | 14.6% | 38.2% | 11.1% | — | 2,431 |
| MDT | $118.8B | 24.9× | 12.6× | 3.3× | 8.4% | 65.0% | 13.2% | 9.7% | 9.4% | 0.2× | 2,114 |
| CVS | $114.7B | 64.9× | 11.5× | 0.3× | 7.8% | 45.0% | 0.4% | 2.4% | 2.4% | 0.0× | 1,795 |
| SYK | $107.1B | 33.4× | 18.4× | 4.3× | 11.2% | 64.0% | 12.9% | 14.5% | 8.5% | 2.5× | 2,196 |
| MCK | $102.5B | 22.9× | 16.2× | 0.3× | 12.4% | 3.6% | 1.2% | -219% | 109% | 1.0× | 1,946 |
| HCA | $96.4B | 15.1× | — | 1.3× | 7.1% | — | 9.0% | -113% | 16.8% | — | 1,346 |
| ELV | $91.4B | 16.4× | 15.5× | 0.5× | 12.5% | 89.4% | 2.8% | 12.9% | 7.6% | 4.2× | 1,397 |
| REGN | $82.6B | 19.0× | 19.8× | 5.8× | 1.0% | — | 31.4% | 14.4% | 13.6% | 0.5× | 1,336 |
| CI | $72.7B | 12.4× | 5.5× | 0.3× | 11.2% | 21.8% | 2.2% | 14.3% | 14.1% | 0.0× | 1,583 |
| GTBIF | $1.7B | 15.3× | 5.9× | 1.4× | 3.4% | 48.9% | 9.7% | 6.0% | 5.3% | 0.9× | 5 |
Peers = companies sharing GTBIF's sector (Healthcare) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.